Authors:
Decensi, A
Gandini, S
Guerrieri-Gonzaga, A
Johansson, H
Manetti, L
Bonanni, B
Sandri, MT
Barreca, A
Costa, A
Robertson, C
Lien, EA
Citation: A. Decensi et al., Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women, J CL ONCOL, 17(9), 1999, pp. 2633-2638
Authors:
Cobleigh, MA
Vogel, CL
Tripathy, D
Robert, NJ
Scholl, S
Fehrenbacher, L
Wolter, JM
Paton, V
Shak, S
Lieberman, G
Slamon, DJ
Citation: Ma. Cobleigh et al., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J CL ONCOL, 17(9), 1999, pp. 2639-2648
Citation: Hd. Thames et al., Frequency of first metastatic events in breast cancer: Implications for sequencing of systemic and local-regional treatment, J CL ONCOL, 17(9), 1999, pp. 2649-2658
Authors:
Day, R
Ganz, PA
Costantino, JP
Cronin, WM
Wickerham, DL
Fisher, B
Citation: R. Day et al., Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 study, J CL ONCOL, 17(9), 1999, pp. 2659-2669
Authors:
Rose, PG
Blessing, JA
Gershenson, DM
McGehee, R
Citation: Pg. Rose et al., Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study, J CL ONCOL, 17(9), 1999, pp. 2676-2680
Authors:
Bonner, JA
Sloan, JA
Shanahan, TG
Brooks, BJ
Marks, RS
Krook, JE
Gerstner, JB
Maksymiuk, A
Levitt, R
Mailliard, JA
Tazelaar, HD
Hillman, S
Jett, JR
Citation: Ja. Bonner et al., Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma, J CL ONCOL, 17(9), 1999, pp. 2681-2691
Authors:
Furuse, K
Fukuoka, M
Kawahara, M
Nishikawa, H
Takada, Y
Kudoh, S
Katagami, N
Ariyoshi, Y
Citation: K. Furuse et al., Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer, J CL ONCOL, 17(9), 1999, pp. 2692-2699
Authors:
Stuschke, M
Eberhardt, W
Pottgen, C
Stamatis, G
Wilke, H
Stuben, G
Stoblen, F
Wilhelm, HH
Menker, H
Teschler, H
Muller, RD
Budach, V
Seeber, S
Sack, H
Citation: M. Stuschke et al., Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: Long-term follow-up and investigationsof late neuropsychologic effects, J CL ONCOL, 17(9), 1999, pp. 2700-2709
Citation: Rf. Devore et al., Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer, J CL ONCOL, 17(9), 1999, pp. 2710-2720
Authors:
Sato, G
Saijo, Y
Uchiyama, B
Kumano, N
Sugawara, S
Fujimura, S
Sato, M
Sagawa, M
Ohkuda, K
Koike, K
Minami, Y
Satoh, K
Nukiwa, T
Citation: G. Sato et al., Prognostic value of nucleolar protein p120 in patients with resected lung adenocarcinoma, J CL ONCOL, 17(9), 1999, pp. 2721-2727
Authors:
Tanaka, F
Kawano, Y
Li, M
Takata, T
Miyahara, R
Yanagihara, K
Ohtake, Y
Fukuse, T
Wada, H
Citation: F. Tanaka et al., Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer, J CL ONCOL, 17(9), 1999, pp. 2728-2736
Authors:
Chapman, PB
Einhorn, LH
Meyers, ML
Saxman, S
Destro, AN
Panageas, KS
Begg, CB
Agarwala, SS
Schuchter, LM
Ernstoff, MS
Houghton, AN
Kirkwood, JM
Citation: Pb. Chapman et al., Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma, J CL ONCOL, 17(9), 1999, pp. 2745-2751
Authors:
O'Day, SJ
Gammon, G
Boasberg, PD
Martin, MA
Kristedja, TS
Guo, M
Stern, S
Edwards, S
Fournier, P
Weisberg, M
Cannon, M
Fawzy, NW
Johnson, TD
Essner, R
Foshag, LJ
Morton, DL
Citation: Sj. O'Day et al., Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma, J CL ONCOL, 17(9), 1999, pp. 2752-2761
Authors:
Yung, WKA
Prados, MD
Yaya-Tur, R
Rosenfeld, SS
Brada, M
Friedman, HS
Albright, R
Olson, J
Chang, SM
O'Neill, AM
Friedman, AH
Bruner, J
Yue, N
Dugan, M
Zaknoen, S
Levin, VA
Citation: Wka. Yung et al., Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse, J CL ONCOL, 17(9), 1999, pp. 2762-2771
Authors:
Fleming, JB
Berman, RS
Cheng, SC
Chen, NP
Hunt, KK
Feig, BW
Respondek, PM
Yasko, AW
Pollack, A
Patel, SR
Burgess, MA
Papadopoulos, NE
Plager, C
Zagars, G
Benjamin, RS
Pollock, RE
Pisters, PWT
Citation: Jb. Fleming et al., Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas, J CL ONCOL, 17(9), 1999, pp. 2772-2780
Authors:
Tabone, MD
Terrier, P
Pacquement, H
Brunat-Mentigny, M
Schmitt, C
Babin-Boilletot, A
Mahmoud, HH
Kalifa, C
Citation: Md. Tabone et al., Outcome of radiation-related osteosarcoma after treatment of childhood andadolescent cancer: A study of 23 cases, J CL ONCOL, 17(9), 1999, pp. 2789-2795
Authors:
Vera, P
Rohrlich, P
Stievenart, JL
Elmaleh, M
Duval, M
Bonnin, F
Bok, B
Vilmer, E
Citation: P. Vera et al., Contribution of single-photon emission computed tomography in the diagnosis and follow-un of CNS toxicity of a cytarabine-containing regimen in pediatric leukemia, J CL ONCOL, 17(9), 1999, pp. 2804-2810
Authors:
Rizzo, JD
Vogelsang, GB
Krumm, S
Frink, B
Mock, V
Bass, EB
Citation: Jd. Rizzo et al., Outpatient-based bone marrow transplantation for hematologic malignancies:Cost saving or cost shifting?, J CL ONCOL, 17(9), 1999, pp. 2811-2818
Authors:
Beran, M
Estey, E
O'Brien, S
Cortes, J
Koller, CA
Giles, FJ
Kornblau, S
Andreeff, M
Vey, N
Pierce, SR
Hayes, K
Wong, GC
Keating, M
Kantarjian, H
Citation: M. Beran et al., Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia, J CL ONCOL, 17(9), 1999, pp. 2819-2830